Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Apremilast - Oral Lichen Planus Trial (APOLP)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03836885
Recruitment Status : Withdrawn (Study was terminated due to delay in enrollment.)
First Posted : February 11, 2019
Last Update Posted : June 25, 2020
Sponsor:
Collaborators:
Celgene
Sunnybrook Research Institute
Information provided by (Responsible Party):
Dr. Hagen Klieb, Sunnybrook Health Sciences Centre

Tracking Information
First Submitted Date  ICMJE February 8, 2019
First Posted Date  ICMJE February 11, 2019
Last Update Posted Date June 25, 2020
Actual Study Start Date  ICMJE November 21, 2019
Actual Primary Completion Date April 22, 2020   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: February 8, 2019)
Assessing treatment success defined as Physician Global Assessment (PhGA) of 0 or 1 [ Time Frame: Baseline to 16 weeks ]
The primary outcome will be assessing treatment success with Apremilast as compared to placebo defined as Physician Global Assessment (PhGA) of 0 or 1.
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: December 24, 2019)
  • Achieving complete remission defined as achieving a score of 0 on PhGA scale [ Time Frame: 12 weeks and 16 weeks ]
    Complete remission is defined as achieving a score of 0 on PhGA scale
  • Physician Global Assessment (PhGA) [ Time Frame: Baseline to 16 weeks ]
    Physician Global Assessment (PhGA) grading score from 0 to 4. Score of 0 is clear, score of 1 is almost clear, score of 2 is mild disease, score of 3 is moderate disease, and a score of 4 is severe disease.
  • Patient Assessment (PtA) [ Time Frame: Baseline to 16 weeks ]
    Patient Assessment (PtA) grading score from 0 to 4. Score of 0 is clear, score of 1 is almost clear, score of 2 is mild disease, score of 3 is moderate disease, and a score of 4 is severe disease.
  • Achieving partial response [ Time Frame: Baseline to 12 weeks ]
    Percentage of patients who achieve partial response
  • Visual Analogue Scale (VAS) [ Time Frame: Baseline to 16 weeks ]
    Patient assessment of pain score from 0 to 10. VAS is a scale demonstrated by a 10 cm horizontal line marked from 0-10 with the left end marked as no symptoms (0) and the right end marked as worst symptoms (10).
  • Oral Health Impact Profile (OHIP-14) Scale [ Time Frame: Baseline to 16 weeks ]
    Patient assessment of overall disease impact on quality of life is a self-filled validated scale that focuses on seven domains: functional limitation, physical pain, psychological discomfort, physical disability, psychological disability, social disability and handicap. Participants will be asked to respond according to frequency of impact on a 5-point scale coded: never (score 0), hardly ever (score 1), occasionally (score 2), fairly often (score 3) and very often (score 4).
  • Modified Oral Mucositis Index (MOMI) Scale [ Time Frame: Baseline weeks to 16 weeks ]
    Physician assessment using a validated 20 item scale in OLP, is used to rate four types of mucosal changes (atrophy, edema, erythema, and ulceration) in nine anatomical areas of the oral cavity
  • Safety and tolerability of Apremilast [ Time Frame: 6 weeks to 16 weeks ]
    Relationship of adverse events to study treatment. Difference in proportions between the two study arms for each AE at each time point will be assessed and changes in the incidence of treatment.
  • Standardized steroid and anti-fungal rinses used [ Time Frame: 6 weeks to 16 weeks ]
    Differences in total dexamethasone and nystatin mouthwashes quantity used at each time point between the two study arms will be assessed
  • Body Mass Index (BMI) [ Time Frame: Baseline to 16 weeks ]
    Differences in BMI scores at each time point between two study arms will be assessed
Original Secondary Outcome Measures  ICMJE
 (submitted: February 8, 2019)
  • Achieving complete remission defined as achieving a score of 0 on PhGA scale [ Time Frame: 12 weeks and 16 weeks ]
    Complete remission is defined as achieving a score of 0 on PhGA scale
  • Physician Global Assessment (PhGA) [ Time Frame: Baseline to 16 weeks ]
    Physician Global Assessment (PhGA) grading
  • Patient Assessment (PtA) [ Time Frame: Baseline to 16 weeks ]
    Patient Assessment (PtA) grading
  • Achieving partial response [ Time Frame: Baseline to 12 weeks ]
    Percentage of patients who achieve partial response
  • Visual Analogue Scale (VAS) [ Time Frame: Baseline to 16 weeks ]
    Patient assessment of pain
  • Oral Health Impact Profile (OHIP-14) Scale [ Time Frame: Baseline to 16 weeks ]
    Patient assessment of overall disease impact on quality of life
  • Modified Oral Mucositis Index (MOMI) Scale [ Time Frame: 6 weeks to 16 weeks ]
    Physician assessment using a validated 20 item scale in OLP, is used to rate four types of mucosal changes (atrophy, edema, erythema, and ulceration) in nine anatomical areas of the oral cavity
  • Safety and tolerability of Apremilast [ Time Frame: 6 weeks to 16 weeks ]
    type, frequency, severity, and relationship of adverse events to study treatment
  • Standardized steroid and anti-fungal rinses used [ Time Frame: 6 weeks to 16 weeks ]
    Differences in total dexamethasone and nystatin mouthwashes quantity used at each time point between the two study arms will be assessed
  • Body Mass Index (BMI) [ Time Frame: Baseline to 16 weeks ]
    Differences in BMI scores at each time point between two study arms will be assessed
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Apremilast - Oral Lichen Planus Trial
Official Title  ICMJE The APOLP Trial: A Single-Center, Randomized, 16 Weeks, Explanatory, Parallel-Group, Superiority, Blinded, Placebo-Controlled, Clinical Trial of Apremilast Use in Oral Lichen Planus
Brief Summary Apremilast for the management of oral lichen planus.
Detailed Description

Oral lichen planus (OLP) affects approximately 1.27% of the general population. Inflammatory responses constitute a major component of OLP pathogenesis where targeted therapies play an important role in managing this condition. Apremilast is a new well-tolerated and relatively safe anti-inflammatory therapy that has been approved for managing psoriasis and psoriatic arthritis. Given its safer profile, Apremilast may ameliorate inflammatory responses in clinically active OLP without the experience of serious adverse events associated with other systemic immunosuppressive therapies used to treat OLP. The plan is to conduct a single-center, explanatory, randomized, 16 weeks, parallel group, superiority, blinded, placebo-controlled, clinical trial.

The main objective is treatment success assessment. Other objectives include exploring the efficacy of Apremilast in clinically active OLP adult patients considered for systemic treatment and failed topical corticosteroid therapy. It is hypothesized that Apremilast will induce more treatment success as compared to placebo in patients who failed the standard treatment of topical corticosteroids.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Condition  ICMJE Oral Lichen Planus
Intervention  ICMJE
  • Drug: Apremilast
    Apremilast tablets. Titration will occur in the initial five days of treatment as per dosing in psoriasis as follows: Day 1: 10 mg; Day 2: 20 mg; Day 3: 30 mg; Day 4: 40 mg; Day 5: 50 mg. Day 6 and thereafter patients will be dosed at 60 mg for a total of 12 weeks.
    Other Name: Otezla
  • Drug: Placebo
    Placebo Oral tablets. Patients randomized to the control arm will receive color, taste, shape and odour matched oral placebo. The number of tablets and the days taken is analogous to the intervention arm had they been randomized to the intervention arm.
Study Arms  ICMJE
  • Experimental: Apremilast
    Oral tablet
    Intervention: Drug: Apremilast
  • Placebo Comparator: Placebo
    Oral tablet
    Intervention: Drug: Placebo
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Withdrawn
Actual Enrollment  ICMJE
 (submitted: June 23, 2020)
0
Original Estimated Enrollment  ICMJE
 (submitted: February 8, 2019)
39
Actual Study Completion Date  ICMJE April 22, 2020
Actual Primary Completion Date April 22, 2020   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

Each participant must meet all of the following inclusion criteria to participate in this study:

  1. Must be 18 years or older at time of consent.
  2. Patients must have clinically active OLP that is being considered for systemic therapy; and an oral biopsy within the last 12 months of randomization showing a lichenoid reaction correlating clinically with OLP.
  3. Must have failed topical corticosteroids therapy. Topical corticosteroid failure is defined as receiving a trial of at least 4 weeks of high potency topical corticosteroids without achieving sufficient improvement by patients.
  4. Must be in general good health (except for disease under study) as judged by the Investigator, based on medical history, physical examination, clinical laboratories, and urinalysis. (NOTE: The definition of good health means a subject does not have uncontrolled significant co-morbid conditions). Laboratory work-up includes the following: complete blood count (CBC), creatinine, albumin, aspartate aminotransferase (AST), alkaline phosphatase (ALP), gamma glutamyl transferase (GGT), total bilirubin, serum, Beta-HCG (if female), Hepatitis C antibodies and HgbA1C.
  5. Male participants must use a recognized effective method of contraception with any female partner (i.e. at a minimum, barrier plus an additional method of contraception) while on investigational product and for at least 4 weeks after taking the last dose of investigational product.
  6. Female participants of childbearing potential (FCBP)† must have a negative pregnancy test at Screening. While on investigational product and for at least 4 weeks after taking the last dose of investigational product, FCBP who engage in activity in which conception is possible must use one of the approved contraceptive§ options described below:

    1. Option 1: Any one of the following highly effective methods: hormonal contraception (oral, injection, implant, transdermal patch, vaginal ring); intrauterine device (IUD); tubal ligation; prior hysterectomy; prior bilateral oophorectomy or salpingo-oophorectomy; or partner's vasectomy;

      OR

    2. Option 2: Male or female condom (latex condom or nonlatex condom NOT made out of natural [animal] membrane [for example, polyurethane]; plus one additional barrier method: (a) diaphragm with spermicide; (b) cervical cap with spermicide; or (c) contraceptive sponge with spermicide.

      • A female of childbearing potential is a sexually mature female who 1) has not undergone a hysterectomy (the surgical removal of the uterus) or bilateral oophorectomy (the surgical removal of both ovaries) or 2) has not been postmenopausal for at least 24 consecutive months (that is, has had menses at any time during the preceding 24 consecutive months).
      • The female subject's chosen form of contraception must be effective by the time the female subject is randomized into the study (for example, hormonal contraception should be initiated at least 28 days before randomization).

Exclusion Criteria:

All participants meeting any of the following exclusion criteria at baseline will be excluded from participation in this study:

  1. Inability to give written consent by the patient or alternative decision maker (will be assessed at screening visit).
  2. Unwillingness to use at least one effective method of contraception due to unknown fetal risks
  3. Use of systemic or topical therapy for OLP other than allowed concomitant care for symptomatic relief in the past 4 weeks.
  4. Hypersensitivity to Apremilast or use of Apremilast within 4 weeks prior to start of study drug. The contraindications to Apremilast use include prior hypersensitivity reactions, breast-feeding, and pregnancy (Uptodate.com® accessed August 1st, 2016). An increased incidence of depression or depressed mood by 1.3% for Apremilast 30 mg BID (twice a day) (OTEZLA® drug monograph accessed August 1st, 2016) was observed in phase 3 psoriasis studies. Celgene suggests that prescribers should carefully weigh the risks and benefits in patients with a history of depression and/or suicidal thoughts or behaviour. The research team will discuss these psychiatric adverse events in the screening visit where patients/caregivers will be instructed to notify the treating team for any mood changes.
  5. History of palpitations/tachyarrhythmia, severe renal impairment (eGFR less than or equal to 29), or lactose intolerance within the past 5 years. Apremilast pills contain lactose; however, the use of concurrent lactase enzyme in lactose intolerant participants will not be considered and lactose intolerant patients will still be excluded even if they take lactase enzyme supplementation. This is explained by the potential exacerbation of gastrointestinal symptoms with Apremilast as an Adverse Event (AE).
  6. CYP3A4 inducers have been shown to diminish Apremilast levels (Lexi-Comp Online™ Interaction Monograph accessed August 1st, 2015); hence, patients will be excluded if they are on concomitant Carbamazepine, Enzalutamide, Fosphenytoin, Lumacaftor, Mitotane, Phenobarbital, Phenytoin, Primidone, Rifabutin, Rifampin, and Rifapentine.
  7. As per Celgene, the presence of any of the following will exclude a subject from enrollment:

    1. Other than disease under study, any clinically significant (as determined by the Investigator) cardiac, endocrinologic, pulmonary, neurologic, psychiatric, hepatic, renal, hematologic, immunologic disease, or other major disease that is currently uncontrolled.
    2. Any condition, including the presence of laboratory abnormalities, which would place the subject at unacceptable risk if he/she were to participate in the study.
    3. Prior history of suicide attempt at any time in the subject's life time prior to screening or randomization, or major psychiatric illness requiring hospitalization within the last 3 years.
    4. Pregnant or breast feeding.
    5. Active substance abuse or a history of substance abuse within 6 months prior to Screening.
    6. Malignancy or history of malignancy, except for:

      • treated [ie, cured] basal cell or squamous cell in situ skin carcinomas;
      • treated [ie, cured] cervical intraepithelial neoplasia (CIN) or carcinoma in situ of cervix with no evidence of recurrence within the previous 5 years.
    7. Use of any investigational drug within 4 weeks prior to randomization, or 5 pharmacokinetic/pharmacodynamic half-lives, if known (whichever is longer).
    8. Prior treatment with apremilast
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Canada
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03836885
Other Study ID Numbers  ICMJE 049-2018
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Responsible Party Dr. Hagen Klieb, Sunnybrook Health Sciences Centre
Study Sponsor  ICMJE Sunnybrook Health Sciences Centre
Collaborators  ICMJE
  • Celgene
  • Sunnybrook Research Institute
Investigators  ICMJE
Principal Investigator: Hagen Klieb, HBSc, MSc, DMD, FRCD(C) Sunnybrook Health Sciences Centre
PRS Account Sunnybrook Health Sciences Centre
Verification Date June 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP